Praluent Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Alirocumab

Indications/Uses

Adjunct to diet & maximally tolerated statin therapy in adults w/ heterozygous familial hypercholesterolemia or clinical atherosclerotic CV disease who require additional lowering of LDL-C. Established atherosclerotic CV disease in adults to reduce CV risk by lowering LDL-C levels in combination w/ max tolerated statin dose w/ or w/o other lipid-lowering therapies or, alone or in combination w/ other lipid-lowering therapies in patients who are statin-intolerant, or for whom statin is contraindicated.

Click to view Praluent detailed prescribing information

Dosage/Direction for Use

SC 75 mg once every 2 wk. Alternative starting dose: 300 mg once every 4 wk.

Click to view Praluent detailed prescribing information

Overdosage

View Praluent overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Praluent detailed prescribing information

Special Precautions

Not to be inj into active skin disease areas or injury eg, sunburns, skin rashes, inflammation or infections. Discontinue use if serious allergic reactions occur. Severe renal & hepatic impairment. Not recommended during pregnancy & lactation. Childn & adolescents <18 yr.

Click to view Praluent detailed prescribing information

Use In Pregnancy & Lactation

Click to view Praluent detailed prescribing information

Adverse Reactions

Local inj site reactions eg, erythema/redness, itching, swelling, pain/tenderness; upper resp tract signs & symptoms eg, oropharyngeal pain, rhinorrhea, sneezing; pruritus.

Click to view Praluent detailed prescribing information

Drug Interactions

Increased target-mediated clearance & reduced systemic exposure w/ statins & other lipid-modifying therapy.

Click to view Praluent detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Praluent detailed prescribing information

Storage

View Praluent storage conditions for details to ensure optimal shelf-life.

Description

View Praluent description for details of the chemical structure and excipients (inactive components).

Action

View Praluent mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Dyslipidaemic Agents

ATC Classification

C10AX14 - alirocumab ; Belongs to the class of other lipid modifying agents.

Regulatory Classification

Presentation/Packing

Form

Praluent soln for inj (pre-filled pen) 150 mg/mL

Packing/Price

1's;2's;6's

Form

Praluent soln for inj (pre-filled pen) 75 mg/mL

Packing/Price

1's;2's;6's

Praluent

alirocumab

Manufacturer:

sanofi-aventis

Distributor:

DKSH